These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 27649312)

  • 1. Immunotherapy for prostate cancer: False promises or true hope?
    Rekoske BT; McNeel DG
    Cancer; 2016 Dec; 122(23):3598-3607. PubMed ID: 27649312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining immunotherapies for the treatment of prostate cancer.
    Redman JM; Gulley JL; Madan RA
    Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
    Antonarakis ES; Drake CG
    Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer immunotherapy.
    May KF; Gulley JL; Drake CG; Dranoff G; Kantoff PW
    Clin Cancer Res; 2011 Aug; 17(16):5233-8. PubMed ID: 21700764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Sun BL
    Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive review of immunotherapies in prostate cancer.
    Maia MC; Hansen AR
    Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
    Laccetti AL; Subudhi SK
    Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular immunotherapy licensed for advanced prostate cancer.
    Traynor K
    Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
    [No Abstract]   [Full Text] [Related]  

  • 13. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
    Stultz J; Fong L
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.
    Prokhnevska N; Emerson DA; Kissick HT; Redmond WL
    Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
    Dawson NA; Roesch EE
    Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
    Singh BH; Gulley JL
    Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
    Cheng ML; Fong L
    Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy: a glimmer of hope for metastatic prostate cancer.
    Jindal V
    Chin Clin Oncol; 2018 Dec; 7(6):61. PubMed ID: 29860848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
    Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
    Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Ă–zdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.